90 related articles for article (PubMed ID: 19620819)
21. Alternative dosing schedules for cetuximab: a role for biweekly administration?
Ramanathan RK
Clin Colorectal Cancer; 2008 Nov; 7(6):364-8. PubMed ID: 19036688
[TBL] [Abstract][Full Text] [Related]
22. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
Loupakis F; Vasile E; Santini D; Masi G; Falcone A; Graziano F
Pharmacogenomics; 2008 Jan; 9(1):55-69. PubMed ID: 18154448
[TBL] [Abstract][Full Text] [Related]
23. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
Watkins D; Cunningham D
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
Hoff PM; Ellis LM; Abbruzzese JL
Oncology (Williston Park); 2004 May; 18(6):736-41; discussion 742, 745-6. PubMed ID: 15214593
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab and cetuximab for colorectal cancer.
Drug Ther Bull; 2006 May; 44(5):37-40. PubMed ID: 16706233
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Xu W; Jing H; Zhang F
Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
[TBL] [Abstract][Full Text] [Related]
27. Cetuximab: from biology to the care of colorectal cancer patients.
Vincenzi B; Santini D; Tonini G
Future Oncol; 2007 Oct; 3(5):497-9. PubMed ID: 17927513
[No Abstract] [Full Text] [Related]
28. Signaling multiplex of the epidermal growth factor receptor.
Higa GM
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1145-56. PubMed ID: 15606339
[TBL] [Abstract][Full Text] [Related]
29. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer.
Mano M; Humblet Y
Nat Clin Pract Oncol; 2008 Jul; 5(7):415-25. PubMed ID: 18506165
[TBL] [Abstract][Full Text] [Related]
30. K-ras mutations and cetuximab in colorectal cancer.
Codacci-Pisanelli G; Spinelli G; Tomao S
N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
[No Abstract] [Full Text] [Related]
31. K-ras mutations and cetuximab in colorectal cancer.
De Roock W; Lambrechts D; Tejpar S
N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
[No Abstract] [Full Text] [Related]
32. Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer.
Korkmaz M; Hendem E; Karakurt Eryılmaz M; Demirkıran A; Karaağaç M; Artaç M
J Oncol Pharm Pract; 2022 Jun; 28(4):998-1002. PubMed ID: 35023411
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers to predict response to anti-EGFR antibodies.
Tejpar S
Clin Adv Hematol Oncol; 2011 Jun; 9(6):486-7. PubMed ID: 21841750
[No Abstract] [Full Text] [Related]
34. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).
Tougeron D; Emambux S; Favot L; Lecomte T; Wierzbicka-Hainaut E; Samimi M; Frouin E; Azzopardi N; Chevrier J; Serres L; Godet J; Levillain P; Paintaud G; Ferru A; Rouleau L; Delwail A; Silvain C; Tasu JP; Morel F; Ragot S; Lecron JC
Oncoimmunology; 2020 Nov; 9(1):1848058. PubMed ID: 33299659
[TBL] [Abstract][Full Text] [Related]
35. Recent developments in colorectal cancer treatment by monoclonal antibodies.
Arsene D; Galais MP; Bouhier-Leporrier K; Reimund JM
Expert Opin Biol Ther; 2006 Nov; 6(11):1175-92. PubMed ID: 17049015
[TBL] [Abstract][Full Text] [Related]
36. [Targeted cancer drugs and their development].
Kaje-Reinikainen S
Duodecim; 2005; 121(2):189; author reply 189. PubMed ID: 15745358
[No Abstract] [Full Text] [Related]
37. Erbitux diagnostic latest adjunct to cancer therapy.
Mitchell P
Nat Biotechnol; 2004 Apr; 22(4):363-4. PubMed ID: 15060535
[No Abstract] [Full Text] [Related]
38. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
Alifrangis L; Schoemaker R; Skartved NJ; Hald R; Montagut C; Kopetz S; Tabernero J; Kragh M; Wade JR
J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):5-18. PubMed ID: 31679083
[TBL] [Abstract][Full Text] [Related]
39. The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.
Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
Expert Opin Emerg Drugs; 2006 Nov; 11(4):665-83. PubMed ID: 17064225
[TBL] [Abstract][Full Text] [Related]
40. Sym004: Truly a New Level of Anti-EGFR Treatment?
Stintzing S; Heinemann V
Cancer Discov; 2015 Jun; 5(6):578-80. PubMed ID: 26037914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
